Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Drug Regulatory Affairs > Regulatory Strategy > Flashcards

Regulatory Strategy Flashcards

1
Q

EMA responsibility

A

for the scientific evalution, supervision and safety monitoring of Medicines in the EU

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

EMA responsibility

A

protects public and animal health in 28 EU Memeber states, and also in th eEuropean Economic Area

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are the Key responsibilities of the EMA (1)

A

Does not directly work on application but delegates the central applications to the national authorities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what are the Key responsibilities of the EMA (2)

A

issues a recommendation to grant or decline MA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

the MAs is granted by who?

A

European Commission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Heads of medicines agencies (HMA) is?

A

a network of the heads of the national competent authorities (NCA) whose organisation are responsible for the regulation of MP for human and veterinary use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

A Marketing Authorisation is

A

License to sell a medicinal product
Applied by pharamceutical company
granted by competent authroity
Assessemnt is benefit/risk based on (safety, efficacy and quality)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How to obtain a Marketing authorisation

A

Centrailzed procedure
mutual recongnition procedure( Decentralized procedure
National procedures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Type of application

A 
Full or full-mixed application (complete dossier)
Generic medicinal product application
Hybrid medicinal product
Similar biologic product 
Well established use
Fixed dose combination
informed consent
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Full application

A

full dossier, quality, nonclinical and clinical data

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Generic

A

Reference product on the market on less than 8 years
Sama qualitative, quantitative composition
same pharamceutical form
bioequivalence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Hybrid (mixed) application

A

Additional non-clinical/clinical data in case:
Product does not meet definition of generic
No BE
changes in the API
Change to API, therapeutic indication, strength, pharamceutical form or route of adminstration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Biosimilars

A

Additional non-clinical/clinical data in case:
Product does not meet definition of generic; esp. Differences relating to raw materials or differences in manufacturing process of biological product and reference product

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Well estabished use

A

WER use of API for at least 10 years

Non-clinical and clinical trial result replaced by literature

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Fixed combination products

A

API used in composition of authroised MPs but not in combination
New non-clinical and clinical data relating to the combination required

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

informed consent/Duplicat

A

MAH allows refernce to data
Product does not meet definition of generic; esp. Differences relating to raw materials or differences in manfacturing prcess of biological product and reference product

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

National procedure is currently only for?

A

MA in one single EU MS
With No existing MA in any other MS and No pending application in any MS
National phase MRP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Mutual recongnition/Decentralised procedure is intended for?

A

Applications for MA in more than one MS( obligatory)

open for all application which do not fall under obligation for CP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Which application full into the MR/DP?

A

New API, generic, informed consent, bibliographic applications, known substances in new
combinations, line extensions, herbal medicinal products, homeopathic products

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

what are other attributes of the MRP/DCP?

A

flexible choise of MS (CMS/RMS)
different trade names and MAH
possibility of repeating the procedure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Timeline for the MRP

A 
Applicant submit application to the RMS and CMS
RMS validates the application (90 days)
RMS distributes assessment report to CMs
CMS validates the application (90 days)
CMS approves the AR
MA in each of the CMS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Timeline for the DCP?

A
  • Applicant submit application to the RMS and CMS
  • RMS validates the application (70 days)
  • RMS distributes the preliminary assessment report to CMS (35 days)
    -RMS sends preliminary assessment report and all comment of the CMS to the applicant
    -Clock stops, applicant repsonds, clock runs (15 days)
    RMS sends draft AR to the CMS and applicant
    -CMS approved the AR (90 days)

MA in each of the RMS and CMS

23
Q

Role of the RMS?

A

provides regulatory and scientifc advide
coordintes Central point between MAA and CMS
Issues Assessemnt report
Referes to CMDh
informs EMA if after referral no consensus
informs MAA and CMS after positive conclusion
Issues FAR (Finals assessment report)
Publishes AR

24
Q

the choice of the RMS is based on?

A

regulatory, strategic and commerical reasons

25
Q

what is set in the MRP?

A

RMS, where dossier was filed nd appoved nationally

26
Q

what does Referral means?

A

if non consent between authorities–> automaticall into referral

27
Q

why do we need the referral?

A

to solve potential safety risk issues (PSRPH) which cannot be solved during procedure

28
Q

are new data allowed in the referral?

A

no

29
Q

what happend if there is no agreement in the referral?

A

move to CHMP by EMA for referral

30
Q

withdrawal in MRP?

A

at any time, except after PSRPH has been raised

31
Q

what happend after withdrawal (MRP)

A

automic referral to CMDh

32
Q

withdrawal in DCP?

A

at any time, except during assessement step II once PSRPH has been raised

33
Q

when is the withdrawal (DCP)

A

after Day 120–> automic referral to CMDh

34
Q

Repeat use MRP involved?

A

include fuher CMs

all ongoing procedures to be finalizes and dossier up-date before entering repeat -use

35
Q

which dossier are update includes in repeat -use MRP

A

– Reponses to previous procedures; variations/ renewals
– Commitments to initially granted MA must be fulfilled
– Additional data to comply with latest requirements, e.g. Risk Management Plan, Environmental
Risk Assessment ( to be added via variation)
– CTD format
– If necessary new studies according to new standards

36
Q

CP allows?

A

Allows the MAh ro market the medicine and make it available throughout the EU on the basis of a single MA

37
Q

CP is compulsory for?

A

• Products derived from biotechnology
• Advanced Therapy Medicina Products (ATMPs) (gene therapy, somatic cell therapy, tissue engineered)
• Orphan medicinal products
• Medicinal products for human use which contain an API authorised in the Union after 20 May 2004 and
which are intended for the treatment of AIDS, cancer, neurodegenerative disorders or diabetes.

38
Q

CP is optional for?

A
  • Medicinal products that contain an API not authorised before 20 May 2004,
  • Constituting a significant therapeutic scientific or technical innovation, or
  • For which an EU authorisation would be in the interest of patients.
39
Q

it is possible to obtained a duplicate MA in CP?

A

yes

40
Q

know the CP timeline application

A

do you know it?

41
Q

the EMa prodcut team is made out of?

A

Product team leader (PLT) and product Team members

42
Q

PLT and PTM?

A

Nominated by EMA
Responsible for handling procedural aspects
Both pre-and post authroization phases

43
Q

PLT is primary conat for? (know to draw the trinagel)

A

the applicant

44
Q

Potential option in the CP are

A
  • Accelerated review
  • Exceptional circumstances
  • Conditional approval
  • Orphan drugs
  • Options for small and medium sized entreprises (SME)
45
Q

Stategic choices: What is the legal basis of your medicical product?
it depends on?

A

– Type of API(s)  new, well-known, if old: how old, chem.-def. or herbal,
– Number of API(s)  known or new combination
– Dosage format
– Available bibliographical data

46
Q

if you there are already existing comparable Mas for your product, what do you go for?

A

– WEU – generic – informed consent

47
Q

Strategic Choices: Market considerations

1. Targted markets?

A

All E member states

Limited number of countires

48
Q

Strategic Choices: Market considerations

2. Expand later

A

– 1st wave with main markets: DCP

– 2nd wave with further markets: RU-MRP

49
Q

Strategic Choices: Market considerations

3. Capability of the organization

A

– Ability to market throughout the EU

50
Q

Strategic Choices: Market considerations

4. New availability on other countries

A

– National MA (for many years) in one country  MRP

51
Q

Strategic Choices: costs /Fees

CP

A

one fee

52
Q

Strategic Choices: costs /Fees

National; MRP/DCP

A

individual fee per memeber state

difference between RMS and CM role

53
Q

Strategic Choices: Timelines

What is the feastes procedure

A

National: individually per country (DE: 7 months but…)
– MRP: national + 90 days (national phase not fixed )
– DCP: 210 days (clock stop )
– CP: 210 days

54
Q

Strategic Choices: Name

what is my branding strategy

A

-CP: One single name!

– MRP / DCP: names can be different in MS

Drug Regulatory Affairs (15 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions